Get started
Author

Nanco Hefting

Observed names: N R Hefting, N. Hefting
Institution: Lundbeck (Denmark)
Observed institution: Lundbeck (Denmark)
ORCID: 0000-0003-3310-3439
Observed ORCID: 0000-0003-3310-3439
OpenAlex ID: A5023091059
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
2023 · Daniel Lee, Mary Slomkowski, et al. · JAMA Neurology · 150
PDF
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder
2018 · Mary Hobart, Aleksandar Skuban, et al. · The Journal of Clinical Psychiatry · 76
Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
2018 · Mary Hobart, Aleksandar Skuban, et al. · Current Medical Research and Opinion · 70
PDF
The cognitive, subjective, and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaints.
1997 · K A Wesnes, R A Faleni, et al. · PubMed · 60
Consistency Checks to Improve Measurement with the Hamilton Rating Scale for Anxiety (HAM-A)
2022 · Jonathan Rabinowitz, Janet B.W. Williams, et al. · Journal of Affective Disorders · 45
Consistency checks to improve measurement with the Hamilton Rating Scale for Depression (HAM-D)
2022 · Jonathan Rabinowitz, Janet B.W. Williams, et al. · Journal of Affective Disorders · 36
PDF
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
2019 · Mary Hobart, Peter Zhang, et al. · Journal of Clinical Psychopharmacology · 30
PDF
A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder
2018 · Michael Bauer, Nanco Hefting, et al. · Acta Neuropsychiatrica · 27
Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey
2022 · C. Fletcher, N. Hefting, et al. · Therapeutic Innovation & Regulatory Science · 26
PDF
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania
2021 · Eduard Vieta, Gary Sachs, et al. · Journal of Psychopharmacology · 25
Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric Disorder
2023 · Elena Polverejan, Michael O’Kelly, et al. · Therapeutic Innovation & Regulatory Science · 22
PDF
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference
2025 · Caroline Ward, Milica Pejović Milovančević, et al. · The Lancet Psychiatry · 20
Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial
2024 · Lori L. Davis, Saloni Behl, et al. · JAMA Psychiatry · 20
PDF
Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer's disease: A 12-week, active-treatment, extension trial
2024 · Saloni Behl, Mary Slomkowski, et al. · Journal of Alzheimer s Disease · 19
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
2018 · Ulla Lepola, Nanco Hefting, et al. · International Journal of Geriatric Psychiatry · 16
PDF
Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer’s dementia
2024 · Juliette Meunier, Kristin Creel, et al. · Frontiers in Neurology · 15
PDF
Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study
2024 · Sarah D. Atkinson, Alpesh Shah, et al. · JAACAP Open · 13
Consistency checks to improve measurement with the Young Mania Rating Scale (YMRS)
2023 · Jonathan Rabinowitz, Robert C. Young, et al. · Journal of Affective Disorders · 9
Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
2021 · Stephen R Marder, Stine R Meehan, et al. · Schizophrenia Bulletin Open · 9
PDF
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer’s Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial
2025 · Alpesh Shah, Alvin Estilo, et al. · CNS Drugs · 8
PDF
A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's disease: Recommendations of the ISCTM Working Group
2020 · Cedric O'Gorman, R. Khoury, et al. · The Journal of Prevention of Alzheimer s Disease · 8
PDF
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents
2025 · Caroline Ward, Ann Childress, et al. · Journal of Child and Adolescent Psychopharmacology · 7
PDF
A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder
2024 · Roger S. McIntyre, Kripa Sundararajan, et al. · Acta Neuropsychiatrica · 7
Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder: A Full-Factorial Randomized Clinical Trial
2025 · Mary Hobart, Denise Chang, et al. · The Journal of Clinical Psychiatry · 5
PDF
Efficacy, Safety and Tolerability of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
2023 · George Grossberg, Daniel Lee, et al. · American Journal of Geriatric Psychiatry · 5
Works count: 44
Citation count: 742
H-index: 15
I10-index: 17
Year
Topic
Type